Five ampouled preparations of interleukin-4
Introduction
Interleukin-4 (IL-4) is a T lymphocyte derived polypeptide possessing a broad spectrum of biological activities (Howard et al., 1982; Yokota et al., 1988) . In addition to inducing proliferation of human B cells, it can stimulate the proliferation of a wide range of cells such as T lymphocytes, mast cells and haemopoietic progenitor cells (Ohara, 1988) . The gene for IL-4 has been cloned and shown to code for Abbreviations:
IL-3. interleukin-3; IL-4. interleukin-4; Rh, rDNA derived human; HSA. human serum albumin.
growth of several different types of tumour cells such as lung tumours, renal cell carcinoma and B lymphomas (Golumbek et al., 1991; Defiance et al.. 1992; Toi et al., 1992; Topp et al., 1993) . This has led to clinical investigations of the therapeutic anticancer potential of IL-4 (Gilleece et al., 1992; Margolin et al.. 1994) .
The majority of bioassays for IL-4 utilise cell lines and thus avoid the donor variation of natural cell preparations (Avanzi et al., 1988; Siegel and Mostowski, 1990) . There are several methods for detecting the activity of IL-4 due to its plietotropic biological properties. IL-4 can induce proliferation, inhibit proliferation, induce expression of proteins on the cell surface and promote secretion of proteins extracellularly (Avanzi et al.. 1988; Topp et al., 1993; Siegel and Mostowski, 1990) . This collaborative study included several different cell line based assays. assays using natural material and immunoassays.
Aims of the study
The aims of the study were to: 1. assess the suitability of the ampouled preparations to serve as international standards (IS) for the bioassay and immunoassay of IL-4; 2. to assay the IL-4 content of the ampouled preparations; 3. to compare the different assay systems for IL-4; 4. to compare the ampouled preparations with local standards.
Materials and methods

Materials for the stud)
Generous gifts of rDNA derived human rhIL-4 were kindly donated by Immunex (USA), Schering Plough (USA), Innogenetics (Belgium), Sandoz (Switzerland) and Glaxo (UK) and rhIL-3 donated by Immunex (USA). The candidate international standards were ampouled according to the procedures used for international biological standards (Annex 4, 40th ECBS Report, 1990 ) and coded as detailed in Table 1 .
Each preparation of rhIL-4 or rhIL-3 was dissolved in 2 or 4 litres of pyrogen-free saline (0.9% NaCl) pH 7.2 (Travenol Laboratories, Thetford, Norfolk, UK) containing 0.2% clinical grade human serum albumin and 0.1% trehalose (Fluka Chemicals, Glossop. Derbyshire, UK). This solution was distributed in 0.5 ml or 1 ml aliquots into 4000 ampoules. The ampouled solution was lyophilised and, after secondary desiccation, the ampoules were sealed under dry nitrogen by heat fusion of the glass and stored at -30°C in the dark.
88/656 has been distributed for use as an interim reference reagent with an assigned unitage of 1000 U/ampoule.
Participants in the stud?
48 laboratories in 16 countries contributed data as part of a joint IL-3 and IL-4 collaborative study (Table 2) . Of these participants, 16 provided assays for both the IL-3 and IL-4 preparations, 12 provided assays for IL-3 preparations only, and 20 provided assays for IL-4 preparations only. In addition, one laboratory (NIBSC) provided additional data on stability. Throughout this report of the study, each laboratory has been identified by a number from 01 to 48, not related to the order of listing in Table 2 . Results reported here include only those from assay systems which were either specific for IL-4 or which gave responses to both IL-3 and IL-4.
Participants were asked to contribute assays for IL-4. These were to include both bioassays and immunoassays, especially if the latter were unique to the laboratory of the participant with respect to the antibodies used.
Each participant was asked to carry out at least two independent assays each including, as far as possible, all of the preparations to be tested. For this study assays were considered independent if the dilutions of the various materials were made from a freshly prepared ampoule or fresh dilutions from an appropriately stored stock solution. Participants were requested to include preferably no less than five dilutions of each ampoule in the linear portion of the dose-response curve. The coefficient variation (CV) is defined as: CV = standard deviation + mean (ECBS Technical Report Series 800, 1990, pp. 181-208) .
Participants were asked to contribute all raw data in standard format together with detailed descriptions of assay methods, including their own calculated estimates of potency.
Included among the coded ampoules were unlabelled ampoules containing formulation without the active component in order to highlight non-specific effects in the assays.
Assay contributed to the study
Details of the assay methods used in the study are shown in Table 3 as extracted from the submissions of the participants. References to the methods used are included in the Reference list.
Statistical analysis
For each assay, the raw responses were plotted against the dilution of the preparation and examined both graphically and using analysis of variance. Groups of raw responses obtained using the same dilution of the same preparation in the same assay were examined for outliers both in terms of the within group variation and in terms of the variation of that group relative to the variation of other groups in the same assay (using the in-house program SCAN (Gaines Das and Rice, 198.5) ).
In most cases the IL-4 preparations showed a significant regression on dose with a relationship which could be reasonably described using a four parameter logistic function.
Where the response showed no regression on dose, as was generally the case for the excipient or for the IL-3 preparations in an assay system which was specific for IL-4 preparations, all such responses were omitted from further analysis. In those assay systems where both IL-3 and IL-4 preparations gave responses which showed a significant relationship with dose, but where the relationship with dose differed markedly between the two types of preparation, the response data for the IL-3 preparation were also deleted from further analysis.
Where assays were carried out on microtitre plates, and only a single plate was used or each plate included a common standard, individual responses were used for analysis and responses from the single plate were analysed as an assay. If such assays extended over several plates, estimates from different plates for the same preparation were combined as geometric means to give a single estimate for each preparation from each assay. Where assays extended over several plates, each of which did not include a common standard, no allowance could be made for a possible difference between plates and the individual responses from the several plates have been analysed together as a single assay. Some laboratories used a degree of replication of plates and independent dilution series within and between plates; for these assays analysis has been carried out using the mean response within a plate or dilution series.
For other assays, for which detailed information about the assay design was generally limited, all individual responses have been combined and analysed as an assay.
Values for the upper and lower asymptotes of the four parameter logistic function were used to transform the raw responses to logit responses which were linearly related to log dose. These transformed responses were then analysed by weighted linear logs of the estimates combined. In a few cases, for which data were insufficient to permit determination of asymptotes, or for which a four parameter logistic function was not a satisfactory description of the dose-response relationship, the available responses from an apparently linear part of the response range were analysed using the customary methods for parallel line assays.
Results
I. Dose-response relationships
It has been our experience in many assay systems that the within assay replication is not representative of the total assay variation. The collaborative study design thus included two identical ampoules of one IL-4 preparation, coded G and M. The difference between the slopes of these two identical preparations provided an additional measure against which the difference between slopes of non-identical preparations could be assessed. The deviation of the observed ratio of activities of these two identical preparations from the expected value of 1 provided a direct measure of the within assay variability inherent in these systems. The between laboratory variability for estimates of this relative activity, expected to be 1 in all assay systems and laboratories, provided a measure of the minimum variability inherent in this study using these assay systems (inherent study variability, SV).
Filler alone
In nearly all assay systems, the excipient preparation gave responses which did not differ significantly from 'control' or zero dose responses and which did not change significantly from one dilution to another and which were therefore omitted from further analysis.
hterleukin-3 (code F) and interleukin-4 (codes G-M)
In the majority of assay systems the log dose-response relationships were adequately described by a four parameter logistic function and the resulting log dose-logit response lines were approximately linear. For some data, estimation of the asymptotes of the four parameter logistic function was either not possible because of limited response ranges or not satis- factory, and analyses were carried out using the linear part of log dose-raw response relationships. The majority of the cell line bioassays were not specific for either the IL-3 or the IL-4 preparations. Where significant cross-reactivity was seen (TFl cell line in laboratories 3. 4, 5, 13. 29, 32 and 33 and M07e cell line in laboratories 4, 18, 28 and 441, the dose levels, and in some cases the form of the dose-response relationships tended to be very different. In these cases the data for the IL-3 preparations were analyzed separately from those for the IL-4 preparations.
Marked anomalies in estimates or within laboratory variances were noted in some assays and in subsequent discussions where deletions of anomalies are noted this will refer to cell line assays in laboratories 11, 12, 28. 30, 41, preparation L. H and in-house standard in some assays from laboratory 13, and immunoassays in laboratories 21, 25, 35, a few assays in laboratory 8 and preparation H in assay 5, laboratory 33.
Data from laboratories 17. 20, 27 and the TFl cell assays from laboratory 34 and from the IL-4 preparation from laboratory 44 have also been excluded from further statistical analysis due to lack of species cross-reactivity in laboratories 20 and 27 and nonquantifiable data in laboratories 17, 34 and 44.
Cell line assay and immunoassays
The IL-4 preparations were examined in 23 cell line assay systems. In ten of these systems, no consistent significant differences were detected between the dose-response lines for the IL-4 preparations. In the remaining systems J or both J and K gave different dose-response lines from the other IL-4 preparations; in two of these the dose-response line for L and in two the dose-response line for H was similar to that for J. Under the conditions of laboratory 4, both the TFl cell line and the M07e cell line distinguished between the IL-4 preparations with, in the case of the M07e cells. the dose-reponse line for J being flattest, those for H and K being somewhat flat, those for G and M being steeper and that for L being steepest; in the case of the TFl cells, the dose-response lines for J and K were flat. those for G and M were intermediate and those for H and L were steep.
The IL-4 preparations were examined in 17 immunoassay systems. In four of these the ampouled preparations were examined for the most part at single dilutions so that dose-response lines were not available for comparison and in five systems no consistent significant differences between the IL-4 preparations were detected. In five of the remaining systems J and K gave different dose-response lines from some or all of the other IL-4 preparations. Preparations G (= M), H or L were also distinguished by some assay systems.
Estimates of the relatice activity of the IL-4 preparations in terms of one another.
Comparisons of each of the ampouled preparations of IL-4 with the interim standard 88/656 (G and M) are shown in Fig. 4 and summarized in Table 4 .
For each of these comparisons, estimates of relative activity obtained using immunoassays were at least IO-fold more variable between laboratories than estimates for the coded duplicates, i.e., the inherent study variability (SV).
Except for the comparison of 92/576 (L) with 88/656, the between laboratory variability for estimates from all cell line assays was about twice that of the SV. However, the between laboratory variabilities for estimates from TFl cell line assays only, comparing 88/682 (HI, 89/668 (K) or 92/576 (L) with 88/656, were similar to the SV. For each of these comparisons except 88/682 (H) with 88/656 (G and Ml, the preparation (J, K or L) appeared to be more biologically active than immunologically active. The ratios of biological to immunological activity, using all cell line assays and all immunoassays were 0.74, 1.60, 1.48 and 1.52 for H, J, K and L respectively.
Comparison of IL-4 preparations
with the various in-house standards. Comparisons of in-house standards of IL-4 with 88/656 (G and M) are summarized in Table 4 . Estimates differed even more widely between assays than did estimates for house standards of IL-3 (between laboratory variability some 30 times the SV for IL-4, some 15 times the SV for IL-3). However, considered overall, there was broad agreement that one ampoule of 88/656 contained 0.1 kg (100 ng) of IL-4.
Stabilig
Ampoules of 88/656 which had been stored at elevated temperatures for more than 5 years were compared with ampoules of 88/656 stored continuously at -20°C using three TFl cell line assays and in two M07e cell line assays. Results from samples stored at 4°C or 37°C did not differ significantly from those obtained using samples stored continuously at -20°C or from one another. Samples stored at 56°C showed a significant loss of activity which may also reflect greater difficulty in reconstitution after extended storage at this temperature. Failure to detect any loss of activity for samples stored at 4°C or 37°C suggests that there is no significant instability.
Discussion
The foremost result generated from the data provided by this study is that in the majority of the assay systems for IL-3 and IL-4 cannot be validly compared with one another and furthermore that the relative activities of pairs of IL-4 preparations may differ depending on the assay system and may not reflect the relative mass contents of ampoules.
This data illustrates a fundamental property of recombinant materials that is not generally taken into account, namely that recombinant preparations of the same mass may have very different biological specific activities (Fig. 1) . This emphasizes the need for a potency standard to be calibrated in biological units and not mass units as these are not equivalent between different recombinant and natural materials.
The need for a single potency standard is evident when comparing the estimates of each preparation to the myriad of in-house standards currently being used. The data in this study illustrate that the interlaboratory variation using in-house standards is at least 5-10 times that using any of the single ampouled preparations included in the study, i.e.. two laboratories can be different by 5-lo-fold when estimating the IL-4 content of the same preparation (Fig. 2) . The use of a single reference standard substantially decreases this inter-laboratory variation, e.g., the reduction in variation when 89/508, J, is compared with 88/656. G and M. rather than with the in-house standards.
It is also clear that estimates of potency derived from immunoassays consistently disagree with those derived from bioassays. The large differences between estimates from different immunoassay systems, suggest that the specific antibody pairs used in each assay recognise different cytokine preparations to unique and variable degrees (Fig. 31 .
The results from this study serve as a reminder that immunoassays may provide precise comparisons of identical preparations or of preparations which are seen to he identical antigenically, hut that the antigenic structures recognized by the immunoassay may not reflect biological activity and may not be valid for comparing interleukins derived from different sources (Figs. 1 and 3) .
The relative activities of the IL-4 preparations were not consistent in all assay systems. Estimates for 89/508, J, compared with 88/656. G and M, or 92/576, L. had larger inter-laboratory variability than other comparisons. The dose-response relations for 89/508, J, were also notable for their differences from the other IL-4 preparations (with the possible exception of 89/668, K in some systems). It is also noted that 89/508, J, is the only IL-4 preparation to have been mutated in specific regions. although it is not known if this accounts for the observed differences. There were no apparent consistent differences observed among the other preparations.
The IL-4 preparation 88/656, G and M, appears equally suitable to any of the other preparations, with the possible exception of 89/508, J, to serve as an intemational standard, and no problems have been reported with its use as an interim standard since 1988. It was therefore agreed that 88/656 be established as the international standard for IL-4 and that it be assigned the unitage of 1000 IU/ampoule (the unitage adopted for its use as an interim standard) (Fig. 4) .
Conclusions
The data contributed to this study illustrate the need for a standard for IL-4 calibrated in specific biological potency units. The results of this study also provide confirmation of the accuracy and precision of bioassays used for calibration purposes and illustrate the possible difficulties in calibration which may arise if the differences in biological and immunological activities are ignored.
Based on the results of this study the preparation in ampoules coded 88/656 was established by the WHO Expert Committee on Biological Standardization (ECBS) as the international standard for IL-4 with an assigned potency of 1000 IU. There are approximately 3400 ampoules of 88/656 available for distribution.
These materials are stored at the National Institute for Biological Standards and Control and are available for world-wide distribution.
